You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Plan Learning Across Textual Observations (PLATO) Phase II

    SBC: LANGUAGE COMPUTER CORPORATION            Topic: DTRA162004

    In Phase II of PLATO, we will develop a prototype plan and goal identification system that employs a rich model of domain actions and events, extracted automatically from a massive amount of real-world domain-relevant information, to model agent-specific action costs and to process sequences of agent actions and events, extracted from text, as an agent plan in progress. The system will be able to ...

    SBIR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  2. Enhanced Treatment Management of Opioid-Dependence in an Office-Based Setting

    SBC: MedicaSafe Inc            Topic: NIDA

    PROJECT SUMMARY ABSTRACT Opioid use disorder is the leading cause of accidental death in the USwith overlethal drug overdoses inSAMHSA estimates thatmillion Americans misuse prescription opioids for non medical purposes annuallyPublic health officials and policymakers have acknowledged the urgent need for innovative approaches to the treatment of those with opioid use disorderin spite of thisthe a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Tau oligomer platform validation using lead series candidate in htau mice

    SBC: OLIGOMERIX INC            Topic: NIA

    TITLETau oligomer platform validation using lead series candidate in htau mice PROJECT SUMMARYSBIR Funding OpportunityAdvancing Research on Alzheimerandapos s DiseaseADand Alzheimerandapos s Disease Related DementiasADRDRRPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand related tauopathiesThere is a critical unmet need for a di ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 103

    Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction

    SBC: Recursion Pharmaceuticals, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Chronic diseases of aging account for a significant proportion of healthcare spending and result in a painful and limiting existence for many tens of millions of Americans and hundreds of millions of people around the world. Recursion Pharmaceuticals has developed a drug discovery platform that re-purposes known drugs for the treatment of such diseases. The pla ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. AMBIENT LIGHT ACTIVATABLE OPSIN BASED THERAPY FOR AGE-RELATED MACULAR DEGENERATION

    SBC: NANOSCOPE TECHNOLOGIES LLC            Topic: NEI

    Severe loss of vision occurs due to age-related macular degeneration (AMD) and approximately 15 million people in the US have some form of AMD, which is expected to double by 2050. Most of the current clinical treatments are primarily focused on slowing down the progression of the disease, as there is neither a cure that can stop the degeneration nor a therapy, other than retinal prostheses, that ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. High-throughput nanoMEA-based Proarrhythmia Assay

    SBC: CURI BIO, INC.            Topic: NHLBI

    PROJECT SUMMARY Failure of new drugs at late stages of development is an extremely costly event commonly associated with the detection of unexpected arrhythmogenic properties in novel drugs Undetected arrhythmia inducing effects are also a common reason for drug withdrawal from the market As a result the FDA now mandates that all new drugs be tested for potential arrhythmogenic properties which ha ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. STEM Interactive Digital Tool to Educate and Promote Hearing Health and Science for 4th to 7th Grade

    SBC: CREARE LLC            Topic: 500

    PROJECT SUMMARY ABSTRACT The National Research Council recognizes that serious computer games can support new inquiry based approaches to science instructionproviding virtual laboratories or field learning experiences that overcome practical and logistical constraints to student investigationsWith the nationally recognized need to encourage and enhance education in the ScienceTechnologyEngineering ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Interstitial Intensity Modulated Photodynamic Therapy Phase II

    SBC: SIMPHOTEK, INC.            Topic: 102

    Photodynamic therapy (PDT) is a cancer treatment that utilizes visible or near-infrared light to activate a light- sensitive drug (photosensitizer, PS) that, in turn, creates reactive singlet oxygen species from ground triplet state oxygen that is present in the tumor. The resulting reactive products induce tissue death. Ideally the reactive species will be produced within only the target volume, ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Fluorescent Diagnostic Agents for Detection, Staging, andIntraoperative Imaging of Tumors

    SBC: Onconano Medicine, Inc.            Topic: NCI

    Abstract The goal of this project is to develop IV injectable fluorescent agents for use in intraoperative imaging of peritoneal metastatic tumors. Significance: Peritoneal metastatic cancers have an incidence of 250,000/per year in the US and are primarily treated with surgery. Complete surgical tumor resection is a gold-standard treatment goal that can increase the 5-year patient survival to 50% ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government